The Paris System for Reporting Urinary Cytology (TPS) was published in November 2015. It focuses on the diagnosis of high-grade urothelial carcinoma (HGUC) and provides criteria with which to define the category of atypical urothelial cells (AUC). The objective of the current study was to compare two 1-year consecutive periods before and after use of TPS. METHODS: A total of 1634 and 1814 urine cytology cases, respectively, were analyzed before and after use of TPS. Histological diagnosis within 6 months was available for 330 and 299 cases, respectively. RESULTS: After use of TPS, the authors reported significantly fewer low-grade urothelial neoplasms (0.94% vs 1.84%; P<.05) and more cases that were suspicious for HGUC (2.09% vs 0.73%; P<.01) compared with before use of TPS. For the AUC category, there was no significant change in frequency noted for before versus after TPS (6.12% vs 5.18%), whereas the rate of detection of HGUC on histology significantly increased after TPS when compared with before TPS (49.02% vs 28.17%; P<.02). For the HGUC category, neither the frequency (4.69% vs 4.47%) nor the risk of malignancy (89.39% vs 91.04% with HGUC on histology) were found to be significantly different when comparing before and after use of TPS. CONCLUSIONS: In the authors' practice, TPS helped to better characterize the categories of AUC, low-grade urothelial neoplasm, and suspicious for HGUC, which were associated with a higher risk of HGUC compared with the authors' previous classification.
INTRODUCTION
Urine cytology is easy to perform and noninvasive, but to our knowledge to date is insufficient alone in the majority of cases for the detection and follow-up of urothelial carcinomas. 1 The performance of urine cytology depends on tumor grade. Its sensitivity is rather high (75%-79%) for detecting high-grade urothelial carcinomas (HGUCs) but is much lower (26%-35%) for the detection of low-grade urothelial carcinomas (LGUCs). 1, 2 Depending on the cytologist, an atypical category commonly was used, but there was no consensus regarding the criteria used for defining this category. 3 Some authors had divided this atypical category into atypical urothelial cells of undetermined significance (AUC-US) and atypical urothelial cells, cannot exclude HGUC (AUC-H) or suspicious for HGUC, as is done for cervical smears or thyroid cytology. 4, 5 To the best of our knowledge, until recently there was no consensus classification for reporting urinary cytology. However, fortunately, in November 2015, The Paris System for Reporting Urinary Cytology (TPS) was published. 6 This classification focuses on the diagnosis of HGUC because it can be reliably diagnosed by cytology and is of importance for clinicians because the majority of invasive urothelial carcinomas are largely represented by HGUC. TPS is a 7-tier classification, taking into account the adequacy of the specimens. For negative cytologies, it specifies negative for HGUC. An AUC category is used, with specific criteria, whereas the categories suspicious for HGUC (SHGUC) and HGUC share similar criteria but differ by the number of cells observed. The criteria for detecting low-grade urothelial neoplasm (LGUN) are so strict that only very few cases can be included in this category. The performance of urine cytology also depends on the number of cells that can be observed and clinical and cystoscopy reports. This latter information is not always available. Because TPS is a new system, it important to determine the risk of malignancy associated with the different categories.
In the study laboratory, we began to use TPS for reporting urine cytology results in October 2015. Before this date, we mainly used 5 categories: 1) unsatisfactory; 2) negative; 3) AUC (cannot exclude LGUC); 4) SHGUC; and 5) HGUC. When it was difficult to establish a diagnosis, we used immunocytochemistry with p53 and Ki-67 antibodies to aid in the diagnosis. 7 After October 2015, we used TPS classification applying the criteria described by Rosenthal et al. 6 Herein we report our experience using this new classification for 1 year (October 1, 2015-September 30, 2016) in comparison with the 1-year use of our previous classification (October 1, 2014 1, -September 30, 2015 . The cytological results were compared with histological diagnosis (when available) obtained within a 6-month delay.
MATERIALS AND METHODS

Technique for Urine Preparation
Urine samples were obtained from voided urine, during or after cystoscopy. Samples were immediately fixed in Carbowax (50% alcohol and 1% polyethylene glycol; Dow Chemical Company, Midland, Michigan) solution (volume/volume) and brought to the laboratory at room temperature within 24 hours. Urine volume ranged from 20 mL to 50 mL. Samples were concentrated through centrifugation to retain 2 mL of cells in Carbowax. Cytocentrifuge slides (CytoSpin; Thermo Fisher Scientific, Villebonsur-Yvette, France) were prepared with 500 lL of concentrated cells. Two cytospin slides for each case were stained using the Papanicolaou method.
Patients and Cytological Classification
From October 1, 2014, to September 30, 2015, a total of 1634 urine specimens from 1273 patients were examined. Cytological results were reported as inadequate, negative, AUC (cannot exclude LGUC), LGUC, suspicious for malignancy, and HGUC. This cohort was identified as before use of TPS (B-TPS). Our negative category included normal urothelial cells, reactive atypia whatever the cause, and polyomavirus infections. Our AUC (cannot exclude LGUC) category included samples with cells with a slightly increased nuclear-to-cytoplasmic ratio and irregular nuclei but not hyperchromatism. The SHGUC category included samples with <5 cells with an increased nuclear-to-cytoplasmic ratio and hyperchromatism and the HGUC category included samples with >5 cells with the same criteria, isolated or in groups.
From October 1, 2015, to September 30, 2016, a total of 1814 urine specimens from 1366 patients were examined. The results were classified according to the criteria defined in TPS 6 and qualified as inadequate, negative (for HGUC), AUC, SHGUC, HGUC, and LGUN. This cohort was identified as after use of TPS (A-TPS).
The origin of the urine sample (kidney, ureter, or bladder) also was indicated in both groups.
Histopathological Results
When available, histopathological results were correlated with cytology for all the categories. Both cohorts had the same follow-up period of 6 months and therefore there was no bias for the B-TPS diagnoses having more time to accumulate follow-up biopsy specimens.
Histopathological results were separated into negative, papillary tumors of low malignant potential (LMP) and LGUC, HGUC, and other carcinomas (nonurothelial tumors, metastatic or not), according to the 2016 World Health Organization classification of urothelial tumors. 8 
Statistical Analysis
Comparison between groups was performed using the chisquare test online (BiostaTGV; INSERM, University Pierre and Marie Curie, Paris, France [https://marne.u707. jussieu.fr/biostatgv/]). The cytology performance was calculated using the online Aly-Abbara test (http://www.alyabbara.com/utilitaires/statistiques/). Sensitivity, specificity, and positive predictive values (PPVs) and negative predictive values (NPVs) were assessed for the cytology categories of LGUN for detecting LMP-LGUC and SHGUC or HGUC for detecting HGUC. The McNemar chi-square test was used to compare the sensitivity, specificity, and positive and negative likelihood values between the cytological classification and histology.
The rates of malignancy were calculated according to the final pathological diagnosis for all cytological categories.
RESULTS
The median age of the patients was 67 years (range, 18-101 years) for B-TPS and was 67 years (range, 18-95 years) for A-TPS. The female-to-male ratio was 1:3.26 for B-TPS and 1:3.21 for A-TPS. Table 1 shows the number and percentages of cases in the different cytological categories B-TPS and A-TPS.
There was no significant difference between B-TPS and A-TPS with regard to the percentages of cases in the categories of inadequate (4.65% vs 3.36%), negative (82.01% vs 83.24%), AUC (6.12% vs 5.18%), HGUC (4.47% vs 4.69%), or other malignancy (0.18% vs 0.5%).
However, in the A-TPS cohort, we reported significantly fewer cases of LGUN (0.94% vs 1.84%; P<.05) and more cases of SHGUC (2.09% vs 0.73%; P<.01) compared with in the B-TPS cohort.
Correlation With Histology
Correlation with histopathology was available for 330 specimens B-TPS and for 299 specimens A-TPS for the different categories. The results, shown as the number and percentages of cases, are shown in Table 2 .
Risk of Malignancy
We then calculated the risk of malignancy for the different categories for B-TPS and A-TPS. The results are shown in Table 3 . For the negative cytology cases, the rates of negative histology, LMP-LGUC, or HGUC were not found to differ for the periods B-TPS and A-TPS.
For the AUC category, there was a significantly higher rate of HGUC on histology in the A-TPS compared with the B-TPS period (49.02% vs 28.17%; P<.02).
For the detection of LMP-LGUC on histology, the performance of cytology (LGUN) was lower A-TPS (45.45%) compared with B-TPS (71.43%), but the difference was not significant. For the A-TPS period, LGUN on cytology turned out to be HGUC on histology for greater than one-half of the cases (6 of 11 cases; 54.55%). This was statistically significant when compared with the period B-TPS (17.86%; P<.02).
For the detection of HGUC on histology, there was no difference noted for the periods B-TPS and A-TPS for the cytological categories of SHGUC and HGUC.
Performance of Cytology B-TPS and A-TPS
We calculated the sensitivity, specificity, PPV, and NPV for B-TPS and A-TPS for the detection of LMP-LGUC and HGUC. The results are shown in Table 4 .
The performance of cytology was not significantly different for B-TPS compared with A-TPS. As expected, the sensitivity of LGUN cytology for detecting LMP-LGUC decreased from 30.77% B-TPS to 10% A-TPS. The sensitivity of the SHGUC cytology to detect HGUC increased from 50% B-TPS to 64.5% A-TPS with comparable specificity. No difference was observed according to the performance of HGUC on cytology to detect HGUC on histology before and after TPS (sensitivity of 82.51% vs 84.72%, respectively, and specificity of 94.25% vs 92.11%, respectively).
DISCUSSION
The use of TPS for reporting urinary cytology results 6, 9 has slightly modified our way of reporting urinary cytology. The criteria for each category helped us to be more objective when analyzing urothelial cell cytology. We were able to compare 2 consecutive 1-year periods, named B-TPS and A-TPS, respectively, each of which included a high number of cases (1634 cases and 1814 cases, respectively). For each period, we were able to obtain a histological examination within 6 months after the cytology examination for 330 samples and 299 samples, respectively, in the B-TPS and A-TPS periods. This helped us to evaluate the rate of malignancy for each category before and after TPS. The populations of these 2 different periods allowed for comparison, which demonstrated no difference according to median age, male-to-female ratio, or follow-up.
We noted a higher frequency of HGUC on histology A-TPS compared with B-TPS. This most likely is due to an increase in the number of patients with HGUC who underwent surgery in the study institution after we moved into a new specialized cancer center in 2014 (this tendency also continued to increase after October 2016; data not shown).
This comparison was possible because the study laboratory used a cytological classification B-TPS that was close to TPS. The same criteria were used for the negative category and the number of cells required represented the main difference between the SHGUC and HGUC categories. In the B-TPS cohort in the current study, we reported only a few cytologies as SHGUC due in part to the low number of abnormal cells (>5 abnormal cells) required for the HGUC category. In the A-TPS cohort in the current study, we reported fewer cases of LGUN compared with in the B-TPS cohort due to the strict criteria required to enter this category.
In our experience, we reported 4.65% and 3.36% unsatisfactory cases, respectively, B-TPS and A-TPS. The majority of these cases corresponded to voided urine specimens. We recommend collecting at least 30 mL of urine as it has been established in TPS, 10 but this condition is not systematically fulfilled in the study institution. Negative urine cytologies represented 82.01% and 83.24% of cases, respectively, B-TPS and A-TPS. When correlated with histology, we were able to observe that approximately 32.85% of cases B-TPS and 35.71% of cases A-TPS were associated with LMP-LGUC. This is not surprising because LMP-LGUC cases usually are not associated with abnormal cytology.
2 This is why the TPS focuses on the diagnosis of HGUC. 9 Indeed, histology usually is performed when a tumor is visible at the time of endoscopy. As in the current study, the majority of negative cytologies were not followed by a biopsy; the risk of malignancy for this condition is only indicative and cannot strictly be taken into account. We could observe that <10% of HGUC cases on histology were associated with a negative cytology, which is in accordance with previous reports. For example, Lee et al 11 analyzed the causes of false-negative cytologies for 24 HGUC cases. The pathologist linked a small percentage of these cases (20%) to overestimation of the grade; others were reclassified as AUC using TPS but were obscured by inflammation or poor preservation. 11 In the current study, we reviewed the false-negative cases, which were found to be true false-negative results. AUC represented 6.12% and 5.18% of the cases, respectively, B-TPS and A-TPS. Other authors 12 14 TPS clearly defines the cytological diagnosis of HGUC. In the current study, the frequency of cytological HGUC did not significantly change with TPS. The rate of malignancy (all urothelial carcinomas) was >91% both B-TPS and A-TPS. A-TPS, no LMP-LGUC were classified as cytological HGUC. Indeed, we were able to note a slightly higher rate of detection of HGUC A-TPS (91.04%) compared with B-TPS (89.39%) may be due to more LGUN cases being upgraded as HGUC on cytology A-TPS. The use of TPS also improved the diagnosis of HGUC in a study reviewing 112 cytologies from HGUC proven histology specimens. 15 In the current series, some cytological HGUC cases were not proven on histology (5 in the B-TPS period and 6 in the A-TPS period). We reviewed these cases and confirmed the cytological diagnosis. All cases were from patients with a history of HGUC involving the upper tract and the biopsy could not reach the lesion. For the detection of HGUC, TPS did not change the sensitivity, specificity, PPV, or NPV of urine cytology with values that were in accordance with the literature. 1, 16 For the SHGUC category, we reported significantly more cytologies in this category using TPS. It is interesting to note that B-TPS, we aimed to avoid this category because some clinicians could misinterpret it. between bladder washing and voided urine specimens according to the cytological features of low-grade tumors. This underscores the difficulty of diagnosing LGUN on cytology. However, greater than one-half of our diagnoses (6 of 11 diagnoses) were found to be HGUC on biopsy. This is in relation with the World Health Organization classification, which concludes HGUC even if the majority of the tumor is LGUC. When we re-examined these cytologies, we were unable to find typical cells with high-grade characteristics. In fact, the majority of these cases corresponded to papillary tumors with predominant LGUC and a small area of HGUC. Ancillary tests may be of help in such cases. Piaton et al 18 recently reported interest in dual labeling using p16 and Ki-67 for AUC and LGUN for the prediction of outcome in patients with urothelial carcinomas. Such a test is easy to perform and could be used daily to help characterize such cytologies.
